A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers

PLoS One. 2024 Sep 10;19(9):e0306176. doi: 10.1371/journal.pone.0306176. eCollection 2024.

Abstract

Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. The goals of this protocol are to use these indicators shortly after birth to differentiate newborns who will be diagnosed with NOWS from those who will have mild/no withdrawal, to determine if the indicators predict development at 6 and 18 months of age, and to increase NOWS diagnostic sensitivity for earlier, more accurate diagnoses.

MeSH terms

  • Analgesics, Opioid* / adverse effects
  • Biomarkers*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neonatal Abstinence Syndrome* / diagnosis
  • Opioid-Related Disorders / diagnosis
  • Pregnancy

Substances

  • Biomarkers
  • Analgesics, Opioid